[go: up one dir, main page]

PE20010027A1 - Uso de interferon alfa pegilado en pacientes con melanoma - Google Patents

Uso de interferon alfa pegilado en pacientes con melanoma

Info

Publication number
PE20010027A1
PE20010027A1 PE2000000310A PE0003102000A PE20010027A1 PE 20010027 A1 PE20010027 A1 PE 20010027A1 PE 2000000310 A PE2000000310 A PE 2000000310A PE 0003102000 A PE0003102000 A PE 0003102000A PE 20010027 A1 PE20010027 A1 PE 20010027A1
Authority
PE
Peru
Prior art keywords
melanoma
sticked
patients
alpha interferon
patient
Prior art date
Application number
PE2000000310A
Other languages
English (en)
Inventor
Mary Ellen Rybak
Esther Helen Rose
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20010027A1 publication Critical patent/PE20010027A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE AL USO DE INTERFERON ALFA 2a O 2b PEGILADO UTIL PARA EL TRATAMIENTO DE MELANOMA (MELANOMA CUTANEO) EN UN PACIENTE CON MELANOMA QUE HA SIDO QUIRURGICAMENTE REMOVIDO; O EN UN PACIENTE NUEVO; O A UN PACIENTE AL QUE SE LE HA DIAGNOSTICADO RECIENTEMENTE MELANOMA; O HA EXPERIMENTADO TRATAMIENTO O ES INTOLERANTE O RESISTENTE AL INTERFERON ALFA; UTILIZANDOSE 3µg/Kg A 9 µg/Kg UNA VEZ POR SEMANA POR UN PERIODO DE POR LO MENOS 24 MESES; PARA INCREMENTAR EL TIEMPO DE SUPERVIVENCIA LIBRE DE PROGRESION
PE2000000310A 1999-04-08 2000-04-06 Uso de interferon alfa pegilado en pacientes con melanoma PE20010027A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28836699A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
PE20010027A1 true PE20010027A1 (es) 2001-02-05

Family

ID=23106795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000310A PE20010027A1 (es) 1999-04-08 2000-04-06 Uso de interferon alfa pegilado en pacientes con melanoma

Country Status (21)

Country Link
EP (3) EP1043026B1 (es)
JP (1) JP2000319195A (es)
CN (1) CN1390132A (es)
AR (1) AR023398A1 (es)
AT (3) ATE296639T1 (es)
AU (1) AU771569B2 (es)
BR (1) BR0009646A (es)
CA (1) CA2303992A1 (es)
CO (1) CO5170404A1 (es)
CY (1) CY1108922T1 (es)
DE (3) DE60020444T2 (es)
DK (2) DK1535622T3 (es)
ES (2) ES2239954T3 (es)
HU (1) HU230057B1 (es)
MY (1) MY126763A (es)
NO (1) NO328111B1 (es)
PE (1) PE20010027A1 (es)
PT (2) PT1043026E (es)
TW (1) TWI292320B (es)
WO (1) WO2000061175A2 (es)
ZA (1) ZA200108173B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6322413B2 (ja) 2011-03-10 2018-05-09 プロヴェクタス ファーマテック，インク． 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4492537A (en) 1982-12-10 1985-01-08 Awerkamp John B Fluid-operated oil or water well pump
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates

Also Published As

Publication number Publication date
EP2025344A1 (en) 2009-02-18
ATE296639T1 (de) 2005-06-15
ATE496631T1 (de) 2011-02-15
MY126763A (en) 2006-10-31
HK1075416A1 (en) 2005-12-16
EP1043026A3 (en) 2000-12-20
EP2025344B1 (en) 2011-01-26
HUP0200775A3 (en) 2002-09-30
ES2319776T3 (es) 2009-05-12
CO5170404A1 (es) 2002-06-27
PT1043026E (pt) 2005-09-30
ES2239954T3 (es) 2005-10-16
CN1390132A (zh) 2003-01-08
NO20014852L (no) 2001-12-06
NO328111B1 (no) 2009-12-07
AU771569B2 (en) 2004-03-25
CY1108922T1 (el) 2014-07-02
PT1535622E (pt) 2009-03-19
AU4204600A (en) 2000-11-14
WO2000061175A2 (en) 2000-10-19
EP1043026B1 (en) 2005-06-01
HU230057B1 (hu) 2015-06-29
DK1043026T3 (da) 2005-07-04
NO20014852D0 (no) 2001-10-05
DE60041290D1 (de) 2009-02-12
EP1535622A1 (en) 2005-06-01
WO2000061175A3 (en) 2001-02-01
EP1043026A2 (en) 2000-10-11
TWI292320B (en) 2008-01-11
BR0009646A (pt) 2002-02-05
HK1032349A1 (en) 2001-07-20
DE60045591D1 (de) 2011-03-10
EP1535622B1 (en) 2008-12-31
DE60020444T2 (de) 2006-05-04
HUP0200775A2 (en) 2002-08-28
JP2000319195A (ja) 2000-11-21
ATE419001T1 (de) 2009-01-15
DE60020444D1 (de) 2005-07-07
ZA200108173B (en) 2003-01-06
DK1535622T3 (da) 2009-04-20
AR023398A1 (es) 2002-09-04
CA2303992A1 (en) 2000-10-08

Similar Documents

Publication Publication Date Title
UY26483A1 (es) Activadores de la glucoquinasa transolefinica
ES2172288T3 (es) Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
PE20001109A1 (es) Derivados de rivabirina
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
BR0009480A (pt) Soluções de poliuretano com unidades de estrutura de alcoxissilano
IL152770A0 (en) Gabapentin analogues for sleep disorders
DE60121922D1 (de) Verfahren und zusammenstellung für einen suplantataufbau
SE9400935L (sv) Tandarrangemang
KR960700059A (ko) 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes)
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
ZA941525B (en) Use of riluzole in the treatment of nero-AIDS
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
MXPA02006489A (es) Tratamiento para infecciones dna virales.
PE20010027A1 (es) Uso de interferon alfa pegilado en pacientes con melanoma
BR9911005A (pt) Uso de ozÈnio para a preparação de medicamentos para o tratamento de cáries dentárias
ES2108122T3 (es) Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
IL106272A0 (en) Pharmaceutical compositions comprising il-6
ES2178650T3 (es) Uso de terbinafina para el tratamiento terapeutico de neumocitosis.
GB9802542D0 (en) New use
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
PE20010226A1 (es) Uso de interferon modificado con peg para la preparacion de un medicamento para el tratamiento de leucemia mielocitica cronica
MD2053B1 (en) Remedy with interferon inducing action
HU913800D0 (en) Phenyl-ethanol-amino-tetralines' use for the production of medical preparations with antidepressant and antistress effect
ES2166778T3 (es) Factor de crecimiento ii de tipo insulina como agente antitumoral.

Legal Events

Date Code Title Description
FC Refusal